Similar articles

• Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

  Barry MJ, Mulley AJ Jr. Barry MJ, et al. J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10. J Natl Cancer Inst. 2009. PMID: 19276451 No abstract available.
• Efficacy vs effectiveness in prostate-specific antigen screening.

  Albertsen PC. Albertsen PC. J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8. J Natl Cancer Inst. 2010. PMID: 20142583 No abstract available.
• The cautionary tale of PSA testing.

  Hoffman RM, Zeliadt SB. Hoffman RM, et al. Arch Intern Med. 2010 Jul 26;170(14):1262-3. doi: 10.1001/archinternmed.2010.222. Arch Intern Med. 2010. PMID: 20660847 No abstract available.
• [Detection of prostate cancer: yes or no?].

  Van Cangh PJ. Van Cangh PJ. Bull Mem Acad R Med Belg. 2006;161(3-4):159-69. Bull Mem Acad R Med Belg. 2006. PMID: 17172224 Review. French. No abstract available.
• Is screening for prostate cancer the current gold standard?--"no".

  Kramer BS, Gohagan JK, Prorok PC. Kramer BS, et al. Eur J Cancer. 1997 Mar;33(3):348-53. Eur J Cancer. 1997. PMID: 9155515 Review. No abstract available.